Authors: Cindy Serdjebi1, Florine Chandes1, Bastien Lepoivre1, Yvon Julé1
1Biocellvia, Marseille, France
Cindy Serdjebi, R&D Director,
cindy.serdjebi@biocellvia.com
BACKGROUND AND OBJECTIVES
Metabolic dysfunction associated steatohepatitis (MASH) is the most severe form of steatotic liver diseases. Type 2 diabetes mellitus (T2DM) is known as a major risk factor for fibrosis development, and some drugs currently under development in MASH address both health issues, with no drug approved so far. Knowing T2DM patients are at high-risk of severe fibrosis, we have compared fibrosis stages and characteristics of MASH patients according their T2DM status using MorphoQuant, a fully-automated user- independent morphometric software.
